ZBTB1

ZBTB1 is a nuclear BTB/POZ- and C2H2-zinc-finger-containing transcription factor that operates at the intersection of lineage commitment, metabolic adaptation, and genome maintenance. In hematopoietic progenitors, ZBTB1 forms a complex with LMO2 and CBFA2T3 to co-occupy the Tcf7 enhancer, sustaining Notch-responsive T-lineage differentiation capacity; its loss causes complete T-cell deficiency, impaired ILC3 development, and default myeloid differentiation of lymphoid-primed progenitors (PMID:22201126, PMID:36126774, PMID:28915559, PMID:27542215). ZBTB1 directly binds the ASNS promoter to drive asparagine synthetase transcription under amino acid stress, rendering ZBTB1-null cells unable to synthesize asparagine and hypersensitive to L-asparaginase (PMID:32268116). Independent of its transcriptional roles, ZBTB1 uses a UBZ4 domain to recruit phospho-KAP-1 to UV-damaged chromatin, relaxing local chromatin structure so that RAD18 can access PCNA for monoubiquitination and translesion synthesis (PMID:24657165).

1. 2011 Medium

   Establishing that ZBTB1 is a nuclear transcriptional repressor revealed its basic molecular identity — it localizes to nuclear dot-like structures and represses CRE-mediated transcription through both its BTB/POZ domain and zinc finger motifs.

   Evidence Fluorescence microscopy and luciferase reporter assays with domain deletions in COS7 cells

   PMID:21706167

   Open questions at the time

   • Endogenous genomic targets were not identified
   • Mechanism of repression (co-repressor recruitment, histone modification) unknown
   • No assessment in primary cell types
2. 2011 High

   Positional cloning of a T-cell-deficient ENU mutant mouse and retroviral rescue demonstrated that ZBTB1 is a cell-intrinsic determinant of T lymphopoiesis, establishing its first in vivo function.

   Evidence ENU mutagenesis screen, positional cloning, retroviral transduction rescue, somatic reversion in mouse

   PMID:22201126

   Open questions at the time

   • Direct transcriptional targets in T-cell progenitors were not identified
   • Mechanism by which the point mutation disrupts ZBTB1 function was unclear
3. 2014 High

   Discovery of a non-transcriptional role resolved how ZBTB1 contributes to genome integrity: its UBZ4 domain recruits phospho-KAP-1 to UV-damaged chromatin, relaxing chromatin to allow RAD18-dependent PCNA monoubiquitination and translesion synthesis.

   Evidence Reciprocal Co-IP, UBZ4 domain mutagenesis, siRNA depletion, immunofluorescence at UV damage sites, UV survival assays

   PMID:24657165

   Open questions at the time

   • Whether the UBZ4 domain directly binds ubiquitin or a ubiquitinated substrate was not resolved
   • Relevance of this pathway to the lymphoid phenotype was not tested
4. 2016 High

   Epistasis experiments clarified that Zbtb1 protects lymphoid progenitors from replication-stress-induced DNA damage and p53-dependent apoptosis, yet a p53-independent block at DN3 revealed an additional lineage-specification role beyond survival.

   Evidence γH2AX quantification, Bcl2 transgene rescue, p53 knockout epistasis in bone marrow chimeras of ScanT mutant mice

   PMID:27402700

   Open questions at the time

   • Identity of the replication-stress target(s) was not determined
   • Molecular basis of the p53-independent DN3 block remained open
5. 2016 Medium

   Demonstrating that Zbtb1-deficient LMPPs default to myeloid fate even under lymphoid-inducing conditions established ZBTB1 as a gatekeeper of lymphoid versus myeloid lineage choice upstream of survival control.

   Evidence In vitro differentiation assays with gene expression profiling and Bcl2/p53 epistasis in Zbtb1-deficient LMPPs

   PMID:27542215

   Open questions at the time

   • Direct myeloid gene targets repressed by ZBTB1 were not identified
   • Single-lab finding without independent replication
6. 2017 Medium

   Extension of the lymphoid requirement to innate lymphoid cells showed that Zbtb1 is cell-intrinsically required for NKp46+ RORγt+ ILC3 development and T-bet-dependent IFN-γ acquisition.

   Evidence Bone marrow chimeras and OP9-DL1 co-culture with flow cytometry in Zbtb1-deficient mice

   PMID:28915559

   Open questions at the time

   • Direct transcriptional targets in ILC3 progenitors not mapped
   • Single-lab study
7. 2020 High

   Genome-wide CRISPR screens and ChIP revealed that ZBTB1 directly binds the ASNS promoter to drive asparagine synthetase transcription, establishing a metabolic vulnerability: ZBTB1-null leukemia cells cannot synthesize asparagine and are hypersensitive to L-asparaginase.

   Evidence CRISPR screens in multiple leukemia cell lines, ChIP at ASNS promoter, knockout metabolic and survival assays

   PMID:32268116

   Open questions at the time

   • Whether ZBTB1 acts as an activator or relieves a repressor at ASNS was mechanistically unresolved
   • Relevance to non-leukemic contexts not established
8. 2020 Medium

   ChIP showed ZBTB1 occupies the ERα-binding site in the HER2 intron and suppresses HER2 transcription, linking ZBTB1 to tamoxifen resistance in breast cancer through a miR-23b-3p/ZBTB1/HER2 regulatory axis.

   Evidence ChIP at HER2 regulatory sequences, luciferase reporter, ZBTB1 overexpression/knockdown, xenograft model

   PMID:32690611

   Open questions at the time

   • Mechanism of ZBTB1-mediated repression at HER2 locus not defined
   • Single-lab study
9. 2022 High

   Identification of a LMO2/ZBTB1/CBFA2T3 complex co-occupying the Tcf7 enhancer provided the first molecular mechanism for ZBTB1's T-lineage specification role — maintaining Tcf7 expression and Notch responsiveness in lymphoid progenitors.

   Evidence Two-step affinity purification/LC-MS/MS, ChIP-seq co-binding, CRISPR KO, retroviral Tcf7 rescue

   PMID:36126774

   Open questions at the time

   • Whether the complex acts as an activator or prevents silencing was not distinguished
   • Structural basis of the ternary complex unknown
10. 2023 Medium

    Proteomic identification of ZBTB1–EYA3 interaction expanded ZBTB1's partnership repertoire to myoblast differentiation, showing it partners with the phosphatase/transactivator EYA3 to regulate differentiation-associated gene expression.

    Evidence Mass spectrometry-based proteomics, RNA-seq, co-IP in myoblast differentiation system

    PMID:38026174

    Open questions at the time

    • Direct genomic co-occupancy of ZBTB1 and EYA3 not demonstrated
    • Functional significance of EYA3 isoform-specific effects on ZBTB1 activity not resolved

• How ZBTB1's transcriptional and chromatin-remodeling functions are coordinated across its distinct biological roles — T-lineage commitment, metabolic stress response, DNA damage tolerance, and potentially myogenesis — remains an open question, as does whether its activating versus repressing activities are context-determined by distinct partner complexes.
• No structural model of full-length ZBTB1 or its complexes exists
• Genome-wide binding profile in primary hematopoietic progenitors is incomplete
• Relationship between UBZ4-mediated DNA damage function and transcriptional roles is untested